Assessment of Renal Function in Children

Children Requiring Renal Function Assessment

• Children presenting with signs of severe glomerular injury or acute nephritic syndrome, characterized by the abrupt onset of gross hematuria (cola-colored urine), oliguria, edema, and hypertension.
• Children exhibiting nephrotic-range proteinuria, hypoalbuminemia, anasarca, or significant hyperlipidemia, which are classic signs of nephrotic syndrome.
• Children with persistent microscopic hematuria lasting for more than 2 weeks, or those presenting with recurrent gross hematuria accompanied by proteinuria or reduced renal function.
• Infants and children with a history of recurrent febrile urinary tract infections (UTIs), atypical UTIs caused by non-E. coli organisms, or those exhibiting abnormal voiding patterns such as a poor urinary stream, straining, or persistent dribbling.
• Children presenting with unexplained growth retardation, failure to thrive, rickets, or severe refractory anemia, which are frequently associated with advanced chronic kidney disease (CKD) or tubular transport disorders.
• Neonates with a history of perinatal asphyxia, extremely low birth weight, necrotizing enterocolitis, or hemodynamically significant patent ductus arteriosus, as these are high-risk conditions for acute kidney injury (AKI).
• Children with physical examination findings indicative of renal abnormalities, such as palpable abdominal masses (suggesting multicystic dysplastic kidney, polycystic kidney disease, hydronephrosis, or Wilms’ tumor), palpable bladder, or costovertebral angle tenderness.
• Children with systemic diseases known to involve the kidneys, including systemic lupus erythematosus (SLE), IgA vasculitis (Henoch-Schönlein purpura), diabetes mellitus, sickle cell disease, or congenital malformation syndromes.
• Children exposed to nephrotoxic medications, including aminoglycosides, nonsteroidal anti-inflammatory drugs (NSAIDs), colistin, amphotericin B, calcineurin inhibitors, or chemotherapeutic agents.
• Patients demonstrating symptoms of impaired concentrating ability, such as unexplained polyuria, excessive thirst, nocturnal enuresis, or recurrent episodes of severe dehydration.
• Children with a confirmed family history of hereditary nephropathies, polycystic kidney disease, familial hematuria (such as Alport syndrome), or urolithiasis.
• Fetuses and neonates with antenatally detected congenital anomalies of the kidney and urinary tract (CAKUT), particularly those presenting with bilateral hydronephrosis, oligohydramnios, or an abnormal bladder on prenatal ultrasonography.

Tests Used to Assess Renal Function

Glomerular Filtration Rate (GFR) Estimation and Measurement

• Glomerular filtration rate (GFR) is the standard surrogate for assessing overall nephron endowment and kidney function.
• Direct measurement using clearance of exogenous markers (like inulin) is the gold standard but is cumbersome for routine clinical use.
• Estimation of GFR (eGFR) is generally performed using endogenous biomarkers, primarily serum creatinine and cystatin C.

Biomarker / Test	Mechanism and Clinical Utility	Limitations and Nuances
Serum Creatinine	Derived from muscle metabolism and primarily excreted through glomerular filtration; utilized in the bedside Schwartz formula ($eGFR=k\times height/SerumCreatinine$).	Dependent on muscle mass, age, and nutritional status; values do not increase significantly until GFR is reduced by 50%; falsely low in malnutrition.
Serum Cystatin C	A 13.6-kDa protease inhibitor produced by all nucleated cells, freely filtered, and completely reabsorbed/catabolized by the proximal tubule.	Assays may lack standardization across laboratories; however, it is superior to creatinine because it is not affected by muscle mass, gender, or tubular secretion.
Combined eGFR Equations	Incorporates both serum creatinine, cystatin C, height, and blood urea nitrogen (BUN) to improve diagnostic accuracy, especially in CKD staging.	Requires availability of multiple laboratory values and specific patient anthropometrics, which may not always be integrated into electronic health records.
Beta-Trace Protein (BTP) & Beta-2 Microglobulin	Low molecular weight proteins proposed as alternative endogenous markers for GFR estimation, notably useful in newborns and pregnant patients.	Still considered experimental in some regions; combined pediatric equations using these markers require further external validation.
Exogenous Marker Clearance	Direct measurement of GFR using plasma clearance of iohexol, or radionuclide clearance curves (${}^{125}I$-iothalamate, ${}^{99m}Tc$-DTPA, ${}^{51}Cr$-EDTA).	Requires specialized nuclear medicine facilities, involves radiation exposure (for radionuclides), and necessitates precise multi-point blood sampling.

Tubular Function Tests

• Tubular function tests evaluate the kidney’s ability to concentrate urine, maintain acid-base balance, and regulate the excretion or reabsorption of crucial electrolytes and solutes.
• Defects in tubular transport present with non-specific symptoms such as failure to thrive, rickets, and metabolic acidosis without significant initial reductions in GFR.

Tubular Function	Diagnostic Tests and Interpretation
Urine Concentrating Ability	Evaluated via early morning specific gravity (normal >1.015) or maximum urine osmolality; Water Deprivation Test assesses response to desmopressin (DDAVP) to differentiate central from nephrogenic diabetes insipidus (normal response: $>800$ mOsm/kg).
Acid-Base Regulation (Acidification)	Assessed using minimum urine pH (normal $\sim 5.3-5.5$), plasma anion gap, and fractional excretion of bicarbonate; the Short Ammonium Chloride Test or urine-to-blood $PC{O}_2$ gradient (normal $>20$ mm Hg in alkaline urine) help diagnose distal Renal Tubular Acidosis (RTA).
Sodium Handling	Evaluated using the Fractional Excretion of Sodium (FeNa); FeNa $<1\%$ suggests prerenal azotemia (intact tubular reabsorption), whereas FeNa $>2\%$ indicates intrinsic tubular injury such as Acute Tubular Necrosis (ATN).
Phosphate and Glucose Transport	Measured via Tubular Reabsorption of Phosphate (TRP) and tubular maximum for phosphate reabsorption corrected for GFR (TmP/GFR); urinary glucose threshold evaluates proximal tubular function and helps diagnose Fanconi syndrome.
Potassium Regulation	Assessed via the Transtubular Potassium Gradient (TTKG) and fractional excretion of potassium; aids in distinguishing renal vs. extrarenal causes of hyperkalemia/hypokalemia and detecting hypoaldosteronism.

Urinalysis and Urinary Biomarkers

• Urinalysis is a fundamental, non-invasive screening tool utilized for the rapid presumptive diagnosis of renal parenchymal injury, glomerular permeability defects, and urinary tract infections.
• Advanced urinary biomarkers are increasingly researched to identify early acute kidney injury (AKI) before serum creatinine rises.

Test Category	Specific Assessments and Clinical Significance
Urine Dipstick	Qualitatively detects protein, hemoglobin/myoglobin, leukocyte esterase, and nitrites; useful for screening UTIs and initial detection of nephrotic or nephritic syndromes.
Protein Quantification	Spot urine protein-to-creatinine ratio (UPCR) or albumin-to-creatinine ratio (UACR) replaces cumbersome 24-hour urine collections; UPCR $>2.0$ mg/mg defines nephrotic-range proteinuria, indicating severe glomerular barrier dysfunction.
Urine Microscopy	Centrifuged sediment analysis detects specific cellular elements; $>30\%$ dysmorphic RBCs (acanthocytes) or RBC casts confirm glomerular hematuria, while WBC casts suggest pyelonephritis or interstitial nephritis.
Novel AKI Biomarkers	Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), and the TIMP-2/IGFBP-7 product act as early indicators of tubular stress and injury, predicting AKI up to 48 hours prior to functional GFR decline.
Furosemide Stress Test	A functional biomarker test where an intravenous dose of furosemide ($1-1.5$ mg/kg) is administered; a urine output response of $<200$ mL in 2 hours predicts a high risk for progression to severe AKI.